Antibiotic prophylaxis for preventing postorthotopic liver transplant tuberculosis: is there a safe alternative to isoniazid?

1 Tropical and Infectious Diseases Unit, University Hospital of Padua, Padova, Italy 2 Unit of Hepatic Emergencies and Liver Transplantation, University Hospital of Padua, Padova, Italy 3 Department of Medicine, University Hospital of Padua, Padova, Italy 4 Explora Research and Statistical Analysis, University Hospital of Padua, Padova, Italy 5 Hepatobiliary Surgery and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padua, Padova, Italy 6 Multivisceral Transplant Unit, Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padua, Padova, Italy E-mail: fabrizio.vianello@unipd.it

[1]  T. Shim,et al.  Incidence, characteristics, and treatment outcomes of mycobacterial diseases in transplant recipients , 2016, Transplant international : official journal of the European Society for Organ Transplantation.

[2]  Yongbo Tang,et al.  Liver Transplantation in Antituberculosis Drugs-Induced Fulminant Hepatic Failure , 2015, Medicine.

[3]  P. Martín-Dávila,et al.  Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  P. Garner,et al.  Directly observed therapy for treating tuberculosis. , 2015, The Cochrane database of systematic reviews.

[5]  J. Joh,et al.  Tacrolimus as a risk factor for tuberculosis and outcome of treatment with rifampicin in solid organ transplant recipients , 2012, Transplant infectious disease : an official journal of the Transplantation Society.

[6]  R. Angerami,et al.  Is isoniazid safe for liver transplant candidates with latent tuberculosis? , 2012, Transplantation proceedings.

[7]  G. Bou,et al.  Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  D. Maher,et al.  Scale up: meeting targets in global tuberculosis control , 2004, The Lancet.

[9]  T. Starzl,et al.  Successful liver transplantation for isoniazid-induced hepatic failure--a case report. , 1994, Transplantation.

[10]  D. Cohn,et al.  A 62-Dose, 6-Month Therapy for Pulmonary and Extrapulmonary Tuberculosis: A Twice-Weekly, Directly Observed, and Cost-Effective Regimen , 1990 .

[11]  K. Powell,et al.  Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. , 2010, MMWR. Morbidity and mortality weekly report.